Provided by Tiger Trade Technology Pte. Ltd.

Acurx Pharmaceuticals, LLC*

1.47
+0.02001.38%
Post-market: 1.480.0100+0.68%19:17 EDT
Volume:84.59K
Turnover:126.11K
Market Cap:7.75M
PE:-0.48
High:1.53
Open:1.45
Low:1.45
Close:1.45
52wk High:8.34
52wk Low:1.31
Shares:5.27M
Float Shares:4.17M
Volume Ratio:0.18
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0454
EPS(LYR):-5.3153
ROE:-128.11%
ROA:-55.92%
PB:0.95
PE(LYR):-0.28

Loading ...

Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)

TIPRANKS
·
Aug 20

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and Uspto Trademark Allowance for the Company's Brand Name for Ibezapolstat

THOMSON REUTERS
·
Aug 17

Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP)

TIPRANKS
·
Aug 14

Acurx Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Acurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate

Benzinga Earnings
·
Aug 14

Acurx Pharmaceuticals Q2 EPS USD -0.53

THOMSON REUTERS
·
Aug 14

Press Release: Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 Results and Provides Business Update

Dow Jones
·
Aug 14

Acurx Net Loss Flat at $2.26 Million in Q2 2026

Reuters
·
Aug 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13

ACXP Advances Ibezapolstat Trial in High-Risk C. Difficile Patients

TIPRANKS
·
Aug 13

Acurx Pharmaceuticals Inc Expected to Post a Loss of 38 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Acurx Says Japan, Mexico Patent Offices Grant New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Reuters
·
Aug 12

Acurx partners with Leiden University Medical Center to develop its antibiotics

TIPRANKS
·
Aug 10

Acurx Partners with Leiden UMC to Develop First 3D Structure of MRSA PolC Bound to Its Antibiotic Inhibitor

Reuters
·
Aug 10

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase Iiic Inhibitor Antibiotics

THOMSON REUTERS
·
Aug 10

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Acurx Pharmaceuticals (ACXP)

TIPRANKS
·
Aug 03

Acurx Says FDA Open to Single Phase 3 Trial to Support Ibezapolstat CDI NDA Filing

Reuters
·
Aug 03

Acurx Pharmaceuticals - Receives FDA Guidance on Single Phase 3 Trial Nda for Ibezapolstat in Cdi

THOMSON REUTERS
·
Aug 03

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. Difficile Infection

THOMSON REUTERS
·
Aug 03

Acurx Pharmaceuticals - FDA Agrees Nda Filing Possible for Both Treatment and Recurrence Reduction with Successful Trials

THOMSON REUTERS
·
Aug 03